CDKN2C and medullary thyroid gland carcinoma: CDKN2C loss was associated with a higher stage MTC at diagnosis (p = 0.0009) and a worse outcome compared to both MTC with or without somatic RET M918T mutation and exhibited a lower median overall and disease specific survival.